Effect of a desogestrel-containing oral contraceptive on the skin

Katz, Harry Irving; Kempers, Steven; Akin, Mark; Dunlap, Frank E.; Whiting, David; Norbart, T.

doi:10.1080/13625180008500411

Cited by 21 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Testosterone in the serum decreased and SHBG rose during the therapy only for the active treatment group. Treatment of moderate inflammatory acne for 6 months with the three-stage combination desogestrel (50, 100, 150 µg in each case for 1 week) and ethinyl estradiol (35,30,30 µg in each case for 1 week) (Novial ® ) led to an improvement in the skin condition that was comparable to the placebo group (n=82) [320]. The sebum on the cheeks decreased significantly, but not on the forehead.…”

Section: Norgestimatementioning

confidence: 93%

S2k – Guideline on the Therapy of Acne

Nast

Bayerl

Borelli

et al. 2010

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Section: Norgestimatementioning

confidence: 93%

S2k – Guideline on the Therapy of Acne

Nast

Bayerl

Borelli

et al. 2010

J Deutsche Derma Gesell

View full text Add to dashboard Cite

“…45,46 Nine studies evaluated the effects of contraceptives with desogestrel (DSG). [47][48][49][50][51][52][53] Lastly, three studies evaluated gestodene (GSD). [53][54][55] Two studies used norgestimate (NGM).…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

“…A total of 27 studies were evaluated using the Cochrane Risk of Bias tool; 3 studies were considered as low risk of bias, 39,42,44 9 studies were considered as some concerns, 46,47,49,50,55,56,58,59 and 15 studies at high risk. 29,30,33,[35][36][37]41,48,51,52,54,57,60,61 Most studies that were classified as some concerns exhibited deficits in the randomization process while most studies that were classified as high risk demonstrated concerns in the missing outcome data domain.…”

Section: Risk Of Bias and Quality Of The Assessed Studiesmentioning

confidence: 99%

Harms of third- and fourth-generation combined oral contraceptives in premenopausal women: A systematic review and meta-analysis

Flores-Rodríguez

González-Colmenero

García-Leal

et al. 2023

Journal of Investigative Medicine

View full text Add to dashboard Cite

We assessed the available evidence regarding adverse effects on surrogate and patient-important health outcomes of third- and fourth-generation combined oral contraceptives among premenopausal women. We performed a systematic review and meta-analysis including randomized controlled trials and observational studies comparing third- and fourth-generation combined oral contraceptives with other generation contraceptives or placebo. Studies that enrolled women aged 15 to 50 years, with at least three cycles of intervention and 6 months of follow-up were included. A total of 33 studies comprising 629,783 women were included. Low-density lipoprotein cholesterol levels were significantly lower in fourth-generation oral contraceptives (mean differences (MD): −0.24 mmol/L; [95% CI −0.39 to −0.08]), while total cholesterol was significantly increased in levonorgestrel users when compared to third-generation oral contraceptives (MD: 0.27 mmol/L; [95% CI 0.04 to 0.50]). A decreased arterial thrombosis incidence was shown in fourth-generation oral contraceptive users, as compared to levonorgestrel (incidence rate ratio (IRR): 0.41; [95% CI 0.19 to 0.86]). No difference was found in the occurrence of deep venous thrombosis between fourth-generation oral contraceptives and levonorgestrel users (IRR: 0.91; [95% CI 0.66 to 1.27]; p = 0.60; I2 = 0%). Regarding the remaining outcomes, data were heterogeneous and showed no clear difference. In premenopausal women, the use of third- and fourth-generation oral contraceptives is associated with an improved lipid profile and lower risk of arterial thrombosis. Data were inconclusive regarding the rest of outcomes assessed. This review was registered in PROSPERO with CRD42020211133.

show abstract

“…Die 6monatige Behandlung einer mäßig ausgeprägten entzündlichen Akne mit der triphasischen Kombination Desogestrel (50, 100, 150 µg für jeweils 1 Woche) und Ethinylestradiol (35, 30, 30 µg für jeweils 1 Woche) führte zu einer ähnlichen Reduktion der Läsionen wie bei der Gabe von Placebo ( Evidenzebene 1b – eine Studie, n = 82 ) [44]. Das Sebum an den Wangen nahm signifikant ab, an der Stirn allerdings nicht.…”

Section: Kontrazeptiva Mit Progestinen Der 3 Generationunclassified

Therapie der Akne mit Antiandrogenen – Eine evidenzbasierte Übersicht

Zouboulis

2003

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Antiandrogen treatment should be limited to female patients with additional signs of peripheral hyperandrogenism or hyperandrogenemia. In addition, women with late-onset or recalcitrant acne who also desire contraception can be treated with antiandrogens as can those being treated with systemic isotretinoin. Antiandrogen treatment is not appropriate primary monotherapy for noninflammatory and mild inflammatory acne.

show abstract

Effect of a desogestrel-containing oral contraceptive on the skin

Abstract: These results suggest that DSG-OC reduces facial oiliness and may be a useful contraceptive choice for women with this problem.

Cited by 21 publications

References 16 publications

S2k – Guideline on the Therapy of Acne

S2k – Guideline on the Therapy of Acne

Harms of third- and fourth-generation combined oral contraceptives in premenopausal women: A systematic review and meta-analysis

Therapie der Akne mit Antiandrogenen – Eine evidenzbasierte Übersicht

Contact Info

Product

Resources

About